Systematic ReviewSystematic Review
Open Access

Potential therapeutic benefit of ursodeoxycholic acid in the management of non hepato-biliary upper gastrointestinal disorders

Yasir M. Khayyat
Saudi Medical Journal May 2023, 44 (5) 431-439; DOI: https://doi.org/10.15537/smj.2023.44.5.20220886

References

  1. 1.↵
    1. Forte JG,
    2. Lee HC
    . Gastric adenosine triphosphatases: a review of their possible role in HCl secretion. Gastroenterology 1977; 73: 921–926.
    OpenUrlPubMedWeb of Science
  2. 2.↵
    1. Mainie I,
    2. Tutuian R,
    3. Shay S,
    4. Vela M,
    5. Zhang X,
    6. Sifrim D, et al.
    Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006; 55: 1398–1402.
    OpenUrlAbstract/FREE Full Text
  3. 3.
    1. Gasiorowska A,
    2. Navarro-Rodriguez T,
    3. Wendel C,
    4. Krupinski E,
    5. Perry ZH,
    6. Koenig K, et al.
    Comparison of the degree of duodenogastroesophageal reflux and acid reflux between patients who failed to respond and those who were successfully treated with a proton pump inhibitor once daily. Am J Gastroenterol 2009; 104: 2005–2013.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Knowles CH,
    2. Aziz Q
    . Visceral hypersensitivity in non-erosive reflux disease. Gut 2008; 57: 674–683.
    OpenUrlFREE Full Text
  5. 5.↵
    1. Vaezi MF,
    2. Richter JE
    . Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 1996; 111: 1192–1199.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.
    1. Xu ZR,
    2. Li ZS,
    3. Zou DW,
    4. Xu GM,
    5. Ye P,
    6. Sun ZX, et al.
    Role of duodenogastroesophageal reflux in the pathogenesis of esophageal mucosal injury and gastroesophageal reflux symptoms. Can J Gastroenterol 2006; 20: 91–94.
    OpenUrlPubMed
  7. 7.
    1. Gillen P,
    2. Keeling P,
    3. Byrne PJ,
    4. M Healy,
    5. O’Moore RR,
    6. Hennessy TP
    . Implication of duodenogastric reflux in the pathogenesis of Barrett’s oesophagus. Br J Surg 1988; 75: 540–543.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Iftikhar SY,
    2. Ledingham S,
    3. Steele RJ,
    4. Evans DF,
    5. Lendrum K,
    6. Atkinson M, et al.
    Bile reflux in columnar-lined Barrett’s oesophagus. Ann R Coll Surg Engl 1993; 75: 411–416.
    OpenUrlPubMedWeb of Science
  9. 9.↵
    1. Siddiqui A,
    2. Rodriguez-Stanley S,
    3. Zubaidi S, et al.
    Esophageal visceral sensitivity to bile salts in patients with functional heartburn and in healthy control subjects. Dig Dis Sci 2005; 50: 81–85.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Rocha MS,
    2. Herbella FA,
    3. del Grande JC,
    4. Ferreira AT,
    5. Tahan C,
    6. Patti MG
    . Effects of ursodeoxycholic acid in esophageal motility and the role of the mucosa. An experimental study. Dis Esophagus 2011; 24: 291–294.
    OpenUrlPubMed
  11. 11.↵
    1. Dixon MF,
    2. O’Connor HJ,
    3. Axon AT,
    4. King RF,
    5. Johnston D
    . Reflux gastritis: distinct histopathological entity? J Clin Pathol 1986; 39: 524–530.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Bernstein H,
    2. Bernstein C,
    3. Payne CM,
    4. Dvorakova K,
    5. Garewal H
    . Bile acids as carcinogens in human gastrointestinal cancers. Mutat Res 2005; 589: 47–65.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Jolly AJ,
    2. Wild CP,
    3. Hardie LJ
    . Acid and bile salts induce DNA damage in human oesophageal cell lines. Mutagenesis 2004; 19: 319–324.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Schulz KF,
    2. Altman DG,
    3. Moher D. CONSORT
    2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010; 340: c332. 20100323.
    OpenUrlFREE Full Text
  15. 15.↵
    1. von Elm E,
    2. Altman DG,
    3. Egger M,
    4. Pocock SJ,
    5. Gøtzsche PC,
    6. Vandenbroucke JP, et al.
    The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2007; 18: 800–804.
    OpenUrl
  16. 16.↵
    1. Bor S
    . Consensus report on gastroesophageal reflux disease in Turkey. Turk J Gastroenterol 2017; 28: S1–S2.
    OpenUrl
  17. 17.
    1. Chey WD,
    2. Leontiadis GI,
    3. Howden CW,
    4. Moss SF
    . ACG clinical guideline: treatment of Helicobacter pylori Infection. Am J Gastroenterol 2017; 112: 212–239.
    OpenUrlCrossRefPubMed
  18. 18.
    1. di Pietro M,
    2. Fitzgerald RC
    , BSG Barrett’s guidelines working group. Revised British Society of Gastroenterology recommendation on the diagnosis and management of Barrett’s oesophagus with low-grade dysplasia. Gut 2018; 67: 392–393.
    OpenUrlFREE Full Text
  19. 19.
    1. Evans JA,
    2. Chandrasekhara V,
    3. Chathadi KV,
    4. Decker GA,
    5. Early DS, et al.
    ASGE Standards of Practice Committee; Evans JA, Chandrasekhara V, Chathadi KV, Decker GA, Early DS, et al. The role of endoscopy in the management of premalignant and malignant conditions of the stomach. Gastrointest Endosc 2015; 82: 1–8.
    OpenUrlCrossRefPubMed
  20. 20.
    1. Fischbach W,
    2. Malfertheiner P,
    3. Jansen PL,
    4. Bolten W,
    5. Bornschein J,
    6. Buderus S, et al.
    [S2k-guideline Helicobacter pylori and gastroduodenal ulcer disease]. Z Gastroenterol 2016; 54: 327–363.
    OpenUrl
  21. 21.
    1. Fitzgerald RC,
    2. di Pietro M,
    3. Ragunath K,
    4. Ang K,
    5. Kang JY,
    6. Watson P, et al.
    British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut 2014; 63: 7–42.
    OpenUrlAbstract/FREE Full Text
  22. 22.
    1. Fock KM,
    2. Talley NJ,
    3. Fass R,
    4. Goh KL,
    5. Katelaris P,
    6. Hunt R, et al.
    Report of the Asia-Pacific consensus on the management of gastroesophageal reflux disease. J Gastroenterol Hepatol 2004; 19: 357–367.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.
    1. Gupta S,
    2. Li D,
    3. El Serag HB,
    4. Davitkov P,
    5. Altayar O, et al.
    AGA Clinical practice guidelines on management of gastric intestinal metaplasia. Gastroenterology 2020; 158: 693–702.
    OpenUrlPubMed
  24. 24.
    1. Hunt R,
    2. Armstrong D,
    3. Katelaris P,
    4. Afihene M,
    5. Bane, Shobna
    6. Bhatia A, et al.
    World Gastroenterology Organisation Global Guidelines: GERD global perspective on gastroesophageal reflux disease. J Clin Gastroenterol 2017; 51: 467–478.
    OpenUrlPubMed
  25. 25.
    1. Katz PO,
    2. Dunbar KB,
    3. Schnoll-Sussman FH,
    4. Greer KB,
    5. Yadlapati R, et al.
    ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol 2022; 117: 27–56.
    OpenUrlCrossRefPubMed
  26. 26.
    1. Lam SK,
    2. Talley NJ
    . Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998; 13: 1–12.
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.
    1. Malfertheiner P,
    2. Megraud F,
    3. O’Morain CA,
    4. Gisbert JP,
    5. Kuipers EJ, et al.
    Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut 2017; 66: 6–30. 20161005.
    OpenUrlAbstract/FREE Full Text
  28. 28.
    1. Miwa H,
    2. Sato N
    . Functional dyspepsia and Helicobacter pylori infection: a recent consensus up to 1999. J Gastroenterol Hepatol 2000; 15 Suppl: D60–65.
  29. 29.
    1. Muthusamy RM,
    2. Lightdale JR,
    3. Acosta RD,
    4. Chandrasekhara V,
    5. Chathadi KV, et al.
    ASGE Standards of Practice Committee, Muthusamy RM, Lightdale JR, Acosta RD, Chandrasekhara V, Chathadi KV, et al. The role of endoscopy in the management of GERD. Gastrointest Endosc 2015; 81: 1305–1310.
    OpenUrlCrossRef
  30. 30.
    1. Qumseya B,
    2. Sultan S,
    3. Bain P,
    4. Jamil L,
    5. Jacobson B, et al.
    ASGE Standards Of Practice Committee, Qumseya B, Sultan S, Bain P, Jamil L, Jacobson B, et al. ASGE guideline on screening and surveillance of Barrett’s esophagus. Gastrointest Endosc 2019; 90: 335–359.e2.
    OpenUrlCrossRefPubMed
  31. 31.
    1. Shaheen NJ,
    2. Falk GW,
    3. Iyer PG,
    4. Gerson LB
    , American College of Gastroenterology. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol 2016; 111: 30–50.
    OpenUrlCrossRefPubMed
  32. 32.
    1. Shaukat A,
    2. Wang A,
    3. Acosta RD,
    4. Bruining DH,
    5. Chandrasekhara V, et al.
    ASGE Standards of Practice Committee, Shaukat A, Wang A, Acosta RD, Bruining DH, Chandrasekhara V, et al. The role of endoscopy in dyspepsia. Gastrointest Endosc 2015; 82: 227–232. 20150529.
    OpenUrlPubMed
  33. 33.
    1. Spechler sj,
    2. Sharma P,
    3. Souza RF,
    4. Inadomi JM,
    5. Shaheen NJ
    American Gastroenterological Association, Spechler sj, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology 2011; 140: 1084–1091.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.
    1. Syngal S,
    2. Brand RE,
    3. Church JM,
    4. Giardiello FM,
    5. Heather L Hampel, et al.
    ACG Clinical Guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 2015; 110: 223–262.
    OpenUrlCrossRefPubMed
  35. 35.
    1. Yang J,
    2. Gurudu SR,
    3. Koptiuch C,
    4. Agrawal D,
    5. Buxbaum JL,
    6. Fehmi SMA, et al.
    American Society for Gastrointestinal Endoscopy guideline on the role of endoscopy in familial adenomatous polyposis syndromes. Gastrointest Endosc 2020; 91: 963–982.e962.
    OpenUrlPubMed
  36. 36.
    1. Hunt R,
    2. Armstrong D,
    3. Katelaris P,
    4. Afihene M,
    5. Bane A,
    6. Bhatia S, et al.
    Global Perspective on Gastroesophageal Reflux Disease. WGO Global Guidelines 2015: 1–37.
  37. 37.↵
    1. Katelaris P,
    2. Hunt R,
    3. Bazzoli F,
    4. Cohen H,
    5. Fock KM,
    6. Gemilyan M
    . Helicobacter pylori. WGO Global Guidelines 2021: 1–33.
  38. 38.↵
    1. Peng S,
    2. Huo X,
    3. Rezaei D, et al.
    In Barrett’s esophagus patients and Barrett’s cell lines, ursodeoxycholic acid increases antioxidant expression and prevents DNA damage by bile acids. Am J Physiol Gastrointest Liver Physiol 2014; 307: G129–139.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Peng S,
    2. Huo X,
    3. Rezaei D,
    4. Zhang Q,
    5. Zhang XI,
    6. Yu C, et al.
    Opposing effects of bile acids deoxycholic acid and ursodeoxycholic acid on signal transduction pathways in oesophageal cancer cells. European Journal of Cancer Prevention 2016; 25: 368–379.
    OpenUrl
  40. 40.↵
    1. Goldman A,
    2. Condon A,
    3. Adler E,
    4. Minnella M,
    5. Bernstein C,
    6. Bernstein H, et al.
    Protective effects of glycoursodeoxycholic acid in Barrett’s esophagus cells. Dis Esophagus 2010; 23: 83–93.
    OpenUrlCrossRefPubMedWeb of Science
  41. 41.↵
    1. Bozikas A,
    2. Marsman WA,
    3. Rosmolen WD,
    4. van Baal JWPM,
    5. Kulik W,
    6. ten Kate FJW, et al.
    The effect of oral administration of ursodeoxycholic acid and high-dose proton pump inhibitors on the histology of Barrett’s esophagus. Dis Esophagus 2008; 21: 346–354.
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.↵
    1. Banerjee B,
    2. Shaheen NJ,
    3. Martinez JA,
    4. Hsu CH,
    5. Trowers E,
    6. Gibson BA, et al.
    Clinical study of ursodeoxycholic acid in Barrett’s esophagus patients. Cancer Prev Res (Phila) 2016; 9: 528–533.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    1. Stefaniwsky AB,
    2. Tint GS,
    3. Speck J,
    4. Shefer S,
    5. Salen G
    . Ursodeoxycholic acid treatment of bile reflux gastritis. Gastroenterology 1985; 89: 1000–1004.
    OpenUrlPubMedWeb of Science
  44. 44.↵
    1. Silva JG,
    2. Zeitune JM,
    3. Sipahi AM,
    4. Iryia K,
    5. Laudanna AA
    . Ursodeoxycholic acid does not interfere with in vivo Helicobacter pylori colonization. Revista do Hospital das Clínicas 2000; 55: 201–206.
    OpenUrlPubMed
  45. 45.↵
    1. Kim BT,
    2. Kim KM,
    3. Kim KN
    . The Effect of ursodeoxycholic acid on small intestinal bacterial overgrowth in patients with functional dyspepsia: A pilot randomized controlled trial. Nutrients 2020; 12: 1410.
    OpenUrl
  46. 46.↵
    1. Aggio L,
    2. Mastropaolo G,
    3. Di Mario F,
    4. Cannizzaro R,
    5. Naccarato R.
    [Use of ursodeoxycholic acid in the treatment of functional dyspepsia (a double-blind versus placebo study)]. Minerva Dietol Gastroenterol 1986; 32: 303–306.
    OpenUrlPubMed
  47. 47.↵
    1. van Heumen BWH,
    2. Roelofs HMJ,
    3. Vink-Börger ME,
    4. Dekker E,
    5. Mathus-Vliegen EMH,
    6. Dees J, et al.
    Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial. Orphanet J Rare Dis 2013; 8: 118.
    OpenUrl
  48. 48.
    1. van Hoogstraten HJ,
    2. Wolfhagen FH,
    3. van de Meeberg PC,
    4. Kuiper H,
    5. Nix GA,
    6. Becx MC, et al.
    Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses. J Hepatol 1998; 29: 417–423.
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Berkhout M,
    2. Roelofs HMJ,
    3. Friederich P, et al.
    Ursodeoxycholic acid intervention in patients with familial adenomatous polyposis: a pilot study. J Lab Clin Med. 2007; 150: 147–149.
    OpenUrl
  50. 50.↵
    1. Parc Y,
    2. Desaint B,
    3. Fléjou JF, et al.
    The effect of ursodesoxycholic acid on duodenal adenomas in familial adenomatous polyposis: a prospective randomized placebo-control trial. Colorectal Dis 2012; 14: 854–860.
    OpenUrlPubMed
  51. 51.↵
    1. Van Heumen BWH,
    2. Roelofs HMJ,
    3. Te Morsche RHM,
    4. Nagengast FM,
    5. Peters WHM
    . Duodenal mucosal risk markers in patients with familial adenomatous polyposis: Effects of celecoxib/ursodeoxycholic acid co-treatment and comparison with patient controls. Orphanet J Rare Dis 2013; 8: 1–8.
    OpenUrlCrossRefPubMed
  52. 52.↵
    1. Reid BJ
    . Surrogate markers: lessons from the next gen? Cancer Prev Res (Phila) 2016; 9: 512–517.
    OpenUrlAbstract/FREE Full Text
  53. 53.↵
    1. Rosman AS
    . Efficacy of UDCA in treating bile reflux gastritis. Gastroenterology 1987; 92: 269.
    OpenUrlPubMed
  54. 54.↵
    1. Parquet M,
    2. Metman EH,
    3. Raizman A,
    4. Rambaud JC,
    5. Berthaux N,
    6. Infante R.
    Bioavailability, gastrointestinal transit, solubilization and faecal excretion of ursodeoxycholic acid in man. Eur J Clin Invest 1985; 15: 171–178.
    OpenUrlCrossRefPubMedWeb of Science
  55. 55.↵
    1. McQuaid KR,
    2. Laine L,
    3. Fennerty MB,
    4. Souza R,
    5. Spechler SJ
    . Systematic review: the role of bile acids in the pathogenesis of gastro-oesophageal reflux disease and related neoplasia. Aliment Pharmacol Ther 2011; 34: 146–165.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords